sellWeak cluster of 510b5-1 plan
Michelle LaSpaluto sold $4,172 of CMRX
CHIEF FINANCIAL OFFICER at CHIMERIX INC. 1,015 shares at an average of $4.11, traded Jan 30, 2025, filed Jan 31, 2025.
Warning score
17Value
$4,172
1,015 shares
Holdings after
175,237
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- 0Trade size$4k at market
- 0Share of holdings soldSold 0.6% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-002498, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 30, 2025 | SOpen-market sale Common Stock10b5-1 | -1,015 | $4.11 | $4,172 | 175,237 | Jan 31, 2025 |
Related signals
Other insiders at CHIMERIX INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | CHIMERIX INC | Michael Albert Alrutz SVP AND GENERAL COUNSEL | $7,226 1,600 shares | -1% | |
| 26Weak | CHIMERIX INC | Michael T. Andriole PRESIDENT AND CEO | $33k 7,370 shares | -1% | |
| 17Weak | CHIMERIX INC | Michelle LaSpaluto CHIEF FINANCIAL OFFICER | $10k 2,260 shares | -1% | |
| 10Weak | CHIMERIX INC | David Jakeman VP OF FINANCE AND ACCOUNTING | $1,360 300 shares | -0% | |
| 10Weak | CHIMERIX INC | Allen S. Melemed CHIEF MEDICAL OFFICER | $14k 3,065 shares | -2% | |
| 20Weak | CHIMERIX INC | Michael T. Andriole PRESIDENT AND CEO | $9,636 2,350 shares | -0% | |
| 10Weak | CHIMERIX INC | David Jakeman VP OF FINANCE AND ACCOUNTING | $11k 2,800 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.